Truxima
Truxima Truxima (obinutuzumab) is a humanized, glycoengineered type‑II anti‑CD20 monoclonal antibody used primarily in B‑cell malignancies. Mechanism of Action Targeted binding: Recognizes the CD20 antigen on B‑cell surfaces. Enhanced cytotoxicity:…